Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02373072
Other study ID # B7601009
Secondary ID 2014-004389-54
Status Completed
Phase Phase 1
First received
Last updated
Start date March 2015
Est. completion date March 2016

Study information

Verified date January 2017
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a study with two sequential cohorts, each with three treatment periods. Single doses of PF-06649751 will be tested in this study, starting at a low dose and escalating to a dose projected to be under the current limits for drug concentration. Each cohort will aim to achieve approximately 9 completers. Primary endpoint is safety and tolerability, secondary endpoint is MDS-UPDRS part III.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date March 2016
Est. primary completion date February 2016
Accepts healthy volunteers No
Gender All
Age group 30 Years to 85 Years
Eligibility Inclusion Criteria: - L-DOPA-responsiveness - Hoehn & Yahr Stage II-III inclusive - Experiencing motor fluctuations - Stable daily dose of L-DOPA of at least 300 mg - Females on non-childbearing potential and male subjects Exclusion Criteria: - History of troublesome dyskinesias - History of surgical intervention for Parkinson's disease

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PF-06649751
Subjects completing all three treatment periods will be administered two doses. Doses: 0.75mg, 1.5mg, 3mg, 6mg, 9mg. Tablets in the form of 0.25mg or 1 mg.
Trimethobenzamide Hydrochloride
300mg TID, Capsules. Optional in both Cohorts.
Placebo
Subjects completing all three treatment periods will be receiving placebo once.

Locations

Country Name City State
Belgium Pfizer Clinical Research Unit Brussels
United States Atlanta Center for Medical Research Atlanta Georgia
United States SNBL Clinical Pharmacology Center, Inc. Baltimore Maryland
United States Neurology Consultants of Dallas, PA Dallas Texas
United States Walnut Hill Medical Center Dallas Texas
United States Parkinson's Movement Disorder Center of Maryland Elkridge Maryland
United States MD Clinical Hallandale Beach Florida
United States Collaborative Neuroscience Network, LLC. Long Beach California

Sponsors (1)

Lead Sponsor Collaborator
Pfizer

Countries where clinical trial is conducted

United States,  Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number and proportion of subjects with Adverse Events (AEs) Day 1 through 61
Primary Number of participants with vital signs data that meet criteria of potential clinical concern Day 1 through 61
Primary Number of participants with ECG data that meet criteria of potential clinical concern Day 1 through 61
Primary Number of participants with abnormal clinically significant laboratory measurements Day 1 through 61
Primary C-SSRS (suicidality assessment) Day 1 through 61
Secondary MDS-UPDRS part III MDS - Unified Parkinson's Disease Rating Scale Part III Day 1, Periods 1-3
See also
  Status Clinical Trial Phase
Completed NCT04202757 - Intravenous Plasma Treatment for Parkinson's Disease Early Phase 1
Not yet recruiting NCT05103618 - Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA Phase 2
Completed NCT03700684 - Voice Treatment for Parkinson's Disease N/A
Completed NCT05027620 - Feasibility of Motor-cognitive Home Training for Parkinson's Disease Using eHealth Technology N/A
Completed NCT03652363 - GDNF in ideopathicParkinsons Disease Phase 2
Recruiting NCT02960464 - tDCS for Treatment of Depression in Parkinson's Disease N/A
Completed NCT05699161 - Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson Phase 1/Phase 2
Completed NCT03944785 - Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
Completed NCT01227265 - Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037) Phase 3
Terminated NCT01215227 - An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153) Phase 3
Withdrawn NCT05832775 - Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's Phase 1
Active, not recruiting NCT02780895 - Parkinsonian Brain Repair Using Human Stem Cells Phase 1
Recruiting NCT01860794 - Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease Phase 1/Phase 2
Terminated NCT02393027 - Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999 Early Phase 1
Completed NCT02445651 - Physiological Effects of Nutritional Support in Patients With Parkinson's Disease N/A
Completed NCT00437125 - Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease Phase 4
Completed NCT02723396 - Sleep, Awake & Move - Part I
Completed NCT00599339 - Transdermal Rotigotine User Surveillance Study
Suspended NCT05471609 - Sustained Release Oral Formulation for Treatment of Parkinson's Disease Early Phase 1
Completed NCT00160576 - Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias Phase 2